|
|
Blood, 15 April 2005, Vol. 105, No. 8, pp. 3270-3277.
Prepublished online as a Blood First Edition Paper on December 16, 2004; DOI 10.1182/blood-2004-10-3864.
 Previous Article | Next Article 
Submitted October 5, 2004
Accepted December 13, 2004
Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl
Jing Jin Gu, Lalaine Santiago, and Beverly S Mitchell*
Lineberger Comprehensive Cancer Center, Departments of Pharmacology and Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
* Corresponding author; email: mitchell{at}med.unc.edu.
Bcr-Abl tyrosine kinase activity initiates a number of intracellular signaling cascades that result in leukemogenesis. Imatinib mesylate, a specific Bcr-Abl tyrosine kinase inhibitor, has been highly successful in the treatment of chronic myelogenous leukemia. However, the emergence of Imatinib resistance and the incomplete molecular response of a significant number of patients receiving this therapy have led to a search for combinations of drugs that will enhance the efficacy of Imatinib. We have demonstrated that Mycophenolic Acid (MPA), a specific inosine monophosphate dehydrogenase (IMPDH) inhibitor that results in depletion of intracellular guanine nucleotides, is synergistic with Imatinib in inducing apoptosis in Bcr-Abl expressing cell lines. Studies of signaling pathways downstream of Bcr-Abl demonstrated that the addition of MPA to Imatinib reduced the phosphorylation of both Stat5 and Lyn, a Src kinase family member. The phosphorylation of S6 ribosomal protein was also greatly reduced. These results demonstrate that inhibitors of guanine nucleotide biosynthesis may synergize with Imatinib in reducing the levels of minimal residual disease in CML and lay the foundation for clinical trials in which IMPDH inhibitors are added to Imatinib in patients who have suboptimal molecular responses to single agent therapy or who have progressive disease.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Domhan, M. Zeier, and A. Abdollahi
Immunosuppressive therapy and post-transplant malignancy
Nephrol. Dial. Transplant.,
April 1, 2009;
24(4):
1097 - 1103.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Chaigne-Delalande, G. Guidicelli, L. Couzi, P. Merville, W. Mahfouf, S. Bouchet, M. Molimard, B. Pinson, J.-F. Moreau, and P. Legembre
The Immunosuppressor Mycophenolic Acid Kills Activated Lymphocytes by Inducing a Nonclassical Actin-Dependent Necrotic Signal
J. Immunol.,
December 1, 2008;
181(11):
7630 - 7638.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, et al.
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Blood,
September 15, 2006;
108(6):
1809 - 1820.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T.-C. Chou
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
Pharmacol. Rev.,
September 1, 2006;
58(3):
621 - 681.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. G. Karur, C. A. Lowell, P. Besmer, V. Agosti, and D. M. Wojchowski
Lyn kinase promotes erythroblast expansion and late-stage development
Blood,
September 1, 2006;
108(5):
1524 - 1532.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
